MFC-MRD and MFC-LSC-MRD results in intermediate-I patients
| . | . | . | No. of cases evaluated . | . | |
|---|---|---|---|---|---|
| . | Control . | Clofarabine . | Control . | Clofarabine . | P . |
| MRD | |||||
| MFC-MRD1, median % (range) | 0.042 (0.00-3.51) | 0.027 (0.00-3.02) | 35 | 46 | |
| MFC-MRD2, median % (range) | 0.041 (0.00-11.75) | 0.018 (0.00-0.61) | 49 | 44 | .05 |
| MFC-MRD status | |||||
| MFC-MRD1 positive, % (n) | 31.4 (11) | 28.3 (13) | 35 | 46 | |
| MFC-MRD2 positive, % (n) | 28.6 (14) | 20.4 (9) | 49 | 44 | |
| LSCs | |||||
| MFC-LSC1, median % (range) | 0.00 (0.00-0.09) | 0.00 (0.00-0.03) | 31 | 44 | |
| MFC-LSC2, median % (range) | 0.00 (0.00-2.09) | 0.00 (0.00-0.00) | 51 | 39 | .01 |
| MFC-LSC-MRD status | |||||
| MFC-LSC1positive, % (n) | 48.4 (15) | 31.8 (14) | 31 | 44 | |
| MFC-LSC2positive, % (n) | 41.4 (21) | 20.5 (8) | 51 | 39 | |
| . | . | . | No. of cases evaluated . | . | |
|---|---|---|---|---|---|
| . | Control . | Clofarabine . | Control . | Clofarabine . | P . |
| MRD | |||||
| MFC-MRD1, median % (range) | 0.042 (0.00-3.51) | 0.027 (0.00-3.02) | 35 | 46 | |
| MFC-MRD2, median % (range) | 0.041 (0.00-11.75) | 0.018 (0.00-0.61) | 49 | 44 | .05 |
| MFC-MRD status | |||||
| MFC-MRD1 positive, % (n) | 31.4 (11) | 28.3 (13) | 35 | 46 | |
| MFC-MRD2 positive, % (n) | 28.6 (14) | 20.4 (9) | 49 | 44 | |
| LSCs | |||||
| MFC-LSC1, median % (range) | 0.00 (0.00-0.09) | 0.00 (0.00-0.03) | 31 | 44 | |
| MFC-LSC2, median % (range) | 0.00 (0.00-2.09) | 0.00 (0.00-0.00) | 51 | 39 | .01 |
| MFC-LSC-MRD status | |||||
| MFC-LSC1positive, % (n) | 48.4 (15) | 31.8 (14) | 31 | 44 | |
| MFC-LSC2positive, % (n) | 41.4 (21) | 20.5 (8) | 51 | 39 | |
MRD1/LSC1, after cycle 1; MRD2/LSC2, after cycle 2.